Crinetics Pharmaceuticals Inc. (CRNX) on Monday delivered some genuinely promising news for people living with a rare adrenal disorder. The company shared topline results from the fourth cohort of its Phase 2 study testing atumelnant, an investigational pill for congenital adrenal hyperplasia (CAH) and adrenocorticotropic hormone-dependent Cushing's syndrome.

CAH is a genetic condition that throws a wrench in the adrenal glands' ability to produce essential hormones including cortisol, aldosterone, and androgens. It's one of those diseases that doesn't get much headlines but makes life difficult for those who have it.

What the Latest Data Shows

The fourth cohort results look pretty solid. All eight patients who completed the cohort experienced rapid and sustained reductions in androstenedione, a hormone that's elevated in CAH. Even better, seven of those eight patients maintained lower serum androstenedione (A4) levels even after their glucocorticoid doses were reduced to physiologic levels, which is kind of the holy grail here.

At the 80 mg dose, atumelnant achieved a 67% mean reduction in A4 levels. At the same time, 88% of participants who completed 12 weeks of treatment were able to cut their glucocorticoid dose down to physiologic replacement levels. That's important because glucocorticoids come with their own baggage of side effects, so being able to use less while still controlling the disease is a big win.

Safety-wise, the drug appears to be well-behaved. Crinetics reported no serious adverse events and no treatment-related severe adverse events. Nobody dropped out because of side effects, and there were no hepatic transaminase issues, which is always a concern when you're testing new drugs.

Extension Study Reinforces the Findings

An interim snapshot from the first seven patients in the Open-Label Extension of the TouCAHn Trial who completed 13 weeks showed results consistent with Cohort 4, both in terms of serum A4 reductions and glucocorticoid dose reductions.

The safety profile continued to look clean with 25 patients enrolled in the extension study. Investigators haven't observed any serious adverse events, treatment-related severe adverse events, or hepatic transaminase problems to date. Seven participants have now completed over 20 weeks of treatment. Overall, atumelnant has accumulated more than 750 weeks of cumulative adult CAH patient exposure with a growing safety database.

Commercial Progress and Competitive Landscape

Crinetics has other irons in the fire too. The FDA approved the company's Palsonify (paltusotine) in September 2025 for first-line treatment of adults with acromegaly who didn't respond adequately to surgery or can't have surgery. The company recognized over $5 million in revenue from Palsonify during the fourth quarter of 2025, marking early commercial traction.

The CAH treatment landscape saw some movement recently. In December 2025, the FDA rejected Corcept Therapeutics Incorporated's (CORT) New Drug Application for relacorilant for hypertension secondary to hypercortisolism. The FDA said it couldn't arrive at a favorable benefit-risk assessment without additional evidence of effectiveness from Corcept.

Meanwhile, Neurocrine Biosciences, Inc. (NBIX) scored an approval in December 2024 for Crenessity (crinecerfont) as an adjunctive treatment to glucocorticoid replacement for controlling androgens in adult and pediatric patients four years and older with classic CAH. So there's competition emerging in this space.

Crinetics (CRNX) shares jumped 13.19% to $52.89 following the announcement, trading near the stock's 52-week high of $53.55.